Posted by Michael Wonder on 07 Dec 2018
Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs
6 December 2018 - The Canadian patchwork system of prescription drug coverage and the employer sponsored private health benefits group plans appear vulnerable to cost growth due to insufficient balance of power between fragmented public and private buyers, and pharmaceutical manufacturers.
The emergence of “bad” insurance risks caused by new and very expensive treatments featuring high cost specialty medicines – also known as niche buster drugs – exposes this vulnerability.
This study fills a gap in knowledge by seeking to better understanding how Canadian private insurers face the arrival of specialty pharmaceuticals.
